儿童和青少年慢性髓性白血病慢性期管理:国际儿童慢性髓性白血病专家小组推荐
国际儿童CML专家小组基于医学文献、国家标准和成人CML-CP治疗原则,为儿童和青少年CML-CP的诊断、初始治疗、监测、TKI转换、停药标准及异基因HSCT指征提供推荐。治疗根据EUTOS长期生存评分风险组启动第一代或第二代TKI,耐药或毒性时可转换TKI或研发中药物。异基因HSCT不推荐作为儿童CML-CP一线治疗,仅在进展至晚期或多次治疗失败时考虑。
要点
- 根据EUTOS长期生存评分风险组选择第一代或第二代TKI启动治疗。
- 监测结果可支持因耐药或毒性而转换至另一种TKI或研发中药物。
- 异基因HSCT不推荐作为儿童CML-CP一线治疗,进展至晚期或多次治疗失败时考虑。
核心结论
- 专家小组提供儿童和青少年CML-CP的治疗和管理推荐,旨在优化其诊疗和结局。
研究设计与样本
- 国际儿童CML专家小组基于医学文献(包括既往儿童指南)、国家标准和成人CML-CP治疗原则制定推荐。
主要发现
- 儿童和青少年CML-CP的治疗策略已从异基因HSCT转变为TKI。
- 治疗推荐基于根据患者EUTOS长期生存评分风险组启动第一代或第二代TKI。
- 后续步骤基于推荐监测的结果,若存在耐药或毒性可支持转换至另一种TKI或研发中药物。
- 专家小组还提供了关于持续深度分子学缓解的儿童和青少年TKI停药标准的推荐。
- 异基因HSCT不推荐作为儿童CML-CP的一线治疗,但在进展至晚期或多种治疗失败时应考虑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment strategy for children and adolescents with chronic myeloid leukemia in the chronic phase (CML-CP) has evolved from allogeneic hematopoietic stem cell transplantation (HSCT) to tyrosine kinase inhibitors (TKIs). With the advent of next-generation TKIs and new targeted therapies in the CML field, an international pediatric CML expert panel provides recommendations based on the medical literature (including previous pediatric guidelines), national standards, and treatment principles used in adults with CML-CP. Recommendations include diagnosis of the disease and details on managing the initial steps of care of children and adolescents with newly diagnosed CML-CP, including complications such as leukostasis. The treatment recommendations are based on the initiation of therapy with a first- or second-generation TKI according to the allocated European Treatment and Outcome Study (EUTOS) long-term survival score risk group of the patient. The subsequent steps are based on the results of recommended monitoring which can justify a switch to another TKI or a drug in development if there is resistance or toxicity. The panel also provides recommendations regarding the discontinuation criteria for TKIs in children and adolescents in sustained deep molecular response. Allogeneic HSCT is not recommended as the first-line of treatment for children with CML-CP but is to be considered in case of progression to the advanced phase or failure of several lines of treatment. The present treatment and management recommendations are intended to provide advice to clinicians in view of optimizing the care and the outcome of children and adolescents with CML-CP.
引用
- Millot F, Ampatzidou M, Moulik NR, et al. Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations. Leukemia. 2025. PMID: 40044960. doi:10.1038/s41375-025-02543-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。